DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/-INTOLERANT CHRONIC MYELOID LEUKEMIA IN ACCELERATED PHASE: 24-MONTH DATA FROM START-A

被引：0
|
作者：
Rea, D. [1 ]
Dombret, H. [1 ]
Kim, D. W. [2 ]
Rosti, G. [3 ]
Roy, L. [4 ]
Garzon, F. T. [5 ]
Yuan, X. [5 ]
Cortes, J. [6 ]
Guilhot, F. [4 ]
机构：
[1] Hop St Louis, Paris, France
[2] Catholic Univ, St Marys Hosp, Seoul, South Korea
[3] Bologna Univ Hosp, Inst Seragnoli, Bologna, Italy
[4] CHU Poitiers, Poitiers, France
[5] Bristol Myers Squibb Co, Wallingford, CT USA
[6] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0982
引用
收藏
页码：391 / 391
页数：1
相关论文
共 50 条
  • [1] DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/-INTOLERANT CHRONIC MYELOID LEUKEMIA IN BLAST PHASE: 24-MONTH DATA FROM THE START PROGRAM
    Saglio, G.
    Dombret, H.
    Rea, D.
    Corm, S.
    Cortes, J.
    Kim, D. W.
    Garzon, F. T.
    Paliwal, P.
    Baccarani, M.
    Martinelli, G.
    Gambacorti-Passerini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 349 - 349
  • [2] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    Cortes, J.
    Kim, D-W
    Raffoux, E.
    Martinelli, G.
    Ritchie, E.
    Roy, L.
    Coutre, S.
    Corm, S.
    Hamerschlak, N.
    Tang, J-L
    Hochhaus, A.
    Khoury, H. J.
    Bruemmendorf, T. H.
    Michallet, M.
    Rege-Cambrin, G.
    Gambacorti-Passerini, C.
    Radich, J. P.
    Ernst, T.
    Zhu, C.
    Van Tornout, J. M. A.
    Talpaz, M.
    LEUKEMIA, 2008, 22 (12) : 2176 - 2183
  • [3] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    J Cortes
    D-W Kim
    E Raffoux
    G Martinelli
    E Ritchie
    L Roy
    S Coutre
    S Corm
    N Hamerschlak
    J-L Tang
    A Hochhaus
    H J Khoury
    T H Brümmendorf
    M Michallet
    G Rege-Cambrin
    C Gambacorti-Passerini
    J P Radich
    T Ernst
    C Zhu
    J M A Van Tornout
    M Talpaz
    Leukemia, 2008, 22 : 2176 - 2183
  • [4] DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/-INTOLERANT PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: 24-MONTH DATA FROM START-L
    Porkka, K.
    Martinelli, G.
    Ottman, O. G.
    Dombret, H.
    Garzon, F. T.
    Zhu, C.
    Larson, R. A.
    Simonsson, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 1 - 1
  • [5] DASATINIB TREATMENT OF IMATINIB-RESISTANT AND IMATINIB-INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN A CHRONIC PHASE
    Vinogradova, O. Yu.
    Turkina, A. G.
    Vorontsova, A. V.
    Chelysheva, E. Yu.
    Gusarova, G. A.
    Kuznetsov, S. V.
    Goryacheva, S. R.
    Sokolova, M. A.
    Abakumov, E. M.
    Stakhina, O. V.
    Domracheva, E. V.
    Misyurin, A. V.
    Khoroshko, N. D.
    TERAPEVTICHESKII ARKHIV, 2009, 81 (07) : 41 - 46
  • [6] Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
    Guilhot, Francois
    Apperley, Jane
    Kim, Dong-Wook
    Bullorsky, Eduardo O.
    Baccarani, Michele
    Roboz, Gail J.
    Amadori, Sergio
    de Souza, Carmino A.
    Lipton, Jeffrey H.
    Hochhaus, Andreas
    Heim, Dominik
    Larson, Richard A.
    Branford, Susan
    Muller, Martin C.
    Agarwal, Prasheen
    Gollerkeri, Ashwin
    Talpaz, Moshe
    BLOOD, 2007, 109 (10) : 4143 - 4150
  • [7] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [8] Dasatinib Induces Significant Hematologic and Cytogenetic Responses in Patients with Imatinib-resistant or-intolerant Chronic Myeloid Leukemia in Accelerated Phase
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (04) : 23 - U24
  • [9] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [10] Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study.
    Talpaz, M.
    Apperley, J. F.
    Kim, D. W.
    Silver, R. T.
    Bullorsky, E. O.
    Cheng, S.
    Iyer, M.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
12345